Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Gen Virol ; 84(Pt 2): 361-368, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12560568

ABSTRACT

A novel, experimental subunit human immunodeficiency virus (HIV) vaccine, SFV.HIVA, was constructed. This consists of Semliki Forest virus (SFV), which is a suitable vaccine vector for use in humans, and a passenger gene encoding HIVA, which is an immunogen derived from HIV-1 clade A that is being currently tested in clinical trials of combined DNA- and modified vaccinia virus Ankara (MVA)-vectored vaccines in Oxford (UK) and Nairobi (Kenya). In the mouse, the SFV.HIVA vaccine was highly immunogenic for T cell-mediated immune responses and induced T cell memory that lasted for at least 6 months. SFV.HIVA was also compared to the vaccines currently used in the clinical trials and was shown to be as effective in T cell induction as pTHr.HIVA DNA but less immunogenic than MVA.HIVA. When tested in a prime-boost regimen, SFV.HIVA-induced responses could be boosted by MVA.HIVA. This work is a part of a long-term effort to build a panel of subunit vaccines expressing a common immunogen, which will allow both a direct comparison of various vaccine vectors and combined vaccination regimens in humans and provide more flexibility and/or a potential optimization of vaccinations for individuals based on their pre-existing anti-vector immunity.


Subject(s)
AIDS Vaccines , Drug Design , Genetic Vectors , HIV-1/immunology , Semliki forest virus/genetics , Animals , CD8-Positive T-Lymphocytes/immunology , Cell Line , Female , HIV Infections/immunology , HIV Infections/prevention & control , HIV-1/classification , HIV-1/genetics , Humans , Immunization , Immunization Schedule , Immunization, Secondary , Mice , Mice, Inbred BALB C , Vaccines, Synthetic/immunology , Vaccinia virus/genetics , Vaccinia virus/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...